The Bull Rankings scorecard — our quality-growth score is 55.2 / 100, built from three pillars scored 0–100: Quality 94, Growth 49, Value 37 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 12% a year next year, fading to 4% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
United Therapeutics is a quality‑heavy specialty drug company that trades at a P/E of 19.2, comfortably below the healthcare median. Our model gives it a 55.2/100 quality‑growth score, with Quality 94 eclipsing Value 37. The high quality pillar is the story: a 41.6 % profit margin, 20.5 % ROE, and a debt‑to‑equity of 0. The market already prices in a modest 12 % free‑cash‑flow growth that tapers to 4 % by year ten—higher than the 2.5 % revenue growth just reported. That optimism is not a gamble; it reflects the company’s durable moat and strong cash‑flow generation.
What the business actually is
United Therapeutics develops and sells inhaled and oral therapies for pulmonary arterial hypertension (PAH). Its flagship product, Tyvaso DPI, is a dry‑powder inhaler delivered via pre‑filled cartridges, while Nebulized Tyvaso offers a solution for patients who prefer a nebulizer. The company also markets Remodulin (treprostinil injection) and Orenitram (tablet treprostinil) to slow disease progression and improve exercise capacity. Adcirca, an oral PDE‑5 inhibitor, expands the portfolio into a broader PAH patient base. These products serve a niche, high‑margin market with limited competition, driving the company’s revenue engine.
Why it can (and does) keep compounding
The moat is built on clinical differentiation and regulatory exclusivity. Tyvaso DPI’s single‑use cartridge design reduces dosing errors and enhances patient adherence—an advantage hard for competitors to replicate quickly. The company’s 41.6 % profit margin signals efficient manufacturing and pricing power. With a 20.5 % ROE, capital is deployed productively, and the zero debt load eliminates interest drag. Our model’s “Buying back stock” signal confirms that management is returning value to shareholders while maintaining cash‑flow strength. These factors combine to sustain durable high returns over the long haul.
The valuation question
At a P/E of 19.2, United Therapeutics sits near the 40th percentile of healthcare peers, indicating a modest valuation relative to the sector. However, the Value 37 score places the stock on the expensive side when compared to peers and its own historical P/E range. The reverse‑DCF implied growth of 12 % in the first year, declining to 4 % by year ten, is higher than the 2.5 % revenue growth reported for the trailing twelve months. Thus, the market is pricing in a growth premium that exceeds recent performance. If the company can sustain or accelerate its free‑cash‑flow expansion, the current price reflects a realistic upside; if not, the premium may prove over‑stretched.
The bear case
The most glaring weakness is the Value 37 score, signalling that the stock is already priced on a high multiple. A 12 % free‑cash‑flow growth assumption that fades to 4 % may prove overly optimistic if the company’s revenue growth stalls below 2.5 %. Should the market reassess the sustainability of the 41.6 % margin or the durability of the cartridge technology, the price could retract sharply. A concrete trigger would be a margin compression below 35 %, coupled with a decline in free‑cash‑flow growth to 3 % or less.
What would change our mind
- Margin erosion: If the 41.6 % profit margin drops below 35 %, the quality pillar would weaken, eroding the moat.
- Free‑cash‑flow slowdown: A sustained decline in FCF growth to 3 % or less would invalidate the reverse‑DCF assumption.
- Value deterioration: If the stock’s P/E climbs above 25, pushing the Value score below 30, the expensive side of the valuation would become untenable.
Each of these thresholds is measurable and would prompt a reassessment of the current thesis.